Drug intelligence / Profile preview

Dermax

Development stage: Unknown
Lead developer: Dermal Laboratories
Modality: Small Molecules
Administration: Topical

Overview

Dermax is a therapeutic shampoo developed by Diomed Group (through its subsidiary Dermal Laboratories) for the topical treatment of scalp conditions. The primary active ingredient is benzalkonium chloride, a quaternary ammonium antiseptic that exhibits antimicrobial activity against the yeast *Malassezia furfur*, which is known to proliferate on scaly scalps. The product is specifically indicated for the treatment of pityriasis capitis (dandruff) and other seborrhoeic scalp conditions characterized by scaling. The formulation also contains coconut oil, which serves to condition the hair and moisturize the scalp. Dermax is approved for use in adults, children, and the elderly, and is administered topically as a shampoo.

Brand names: Dermax
Other names: Dermax Therapeutic Shampoo

Beyond the preview

Go deeper on Dermax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dermax.

Explore the full profile